Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aromatase Inhibitors Therapy”

271 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 271 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Not applicableStudy completedNCT06307457
What this trial is testing

HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Who this might be right for
Breast Cancer
Pfizer 604
Testing effectiveness (Phase 2)Ended earlyNCT00892268
What this trial is testing

Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain

Who this might be right for
Breast CancerMenopausal SymptomsPain
University of Arizona 68
Not applicableStudy completedNCT03695341
What this trial is testing

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Who this might be right for
Breast Cancer
Fudan University 130
Not applicableStudy completedNCT02804308
What this trial is testing

Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer

Who this might be right for
Breast CancerAromatase InhibitorsPostmenopausal
Universidade Estadual Paulista Júlio de Mesquita Filho 83
Not applicableStudy completedNCT01928186
What this trial is testing

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+7 more
University of Washington 28
Testing effectiveness (Phase 2)Study completedNCT00012025
What this trial is testing

ICI 182780 in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 80
Not applicableStudy completedNCT03069313
What this trial is testing

Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms

Who this might be right for
Relief of Joint Pain
Texas Tech University Health Sciences Center, El Paso 41
Testing effectiveness (Phase 2)Study completedNCT01797120
What this trial is testing

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

Who this might be right for
Metastatic Breast Cancer
PrECOG, LLC. 131
Not applicableLooking for participantsNCT04476485
What this trial is testing

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Who this might be right for
Breast Cancer
Shengjing Hospital 1,000
Large-scale testing (Phase 3)Looking for participantsNCT04111978
What this trial is testing

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Who this might be right for
Ovarian Neoplasm EpithelialFallopian Tube NeoplasmsPeritoneal Neoplasms+3 more
Swiss GO Trial Group 540
Not applicableStudy completedNCT07072013
What this trial is testing

An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,937
Not applicableNot Yet RecruitingNCT07833501
What this trial is testing

Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast Cancer
D'Or Institute for Research and Education 172
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07571928
What this trial is testing

A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia

Who this might be right for
Infertility Due to AzoospermiaInfertility, Male
Martin Blomberg Jensen 15
Large-scale testing (Phase 3)Study completedNCT00301457
What this trial is testing

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

Who this might be right for
Breast Cancer
Maastricht University Medical Center 1,914
Not applicableStudy completedNCT01016665
What this trial is testing

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Who this might be right for
Breast Cancer
Federal University of São Paulo 71
Not applicableLooking for participantsNCT06650423
What this trial is testing

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

Who this might be right for
Early Breast CancerHormone Receptor Positive TumorHER2-negative Breast Cancer
Institute of Oncology Ljubljana 319
Post-approval studies (Phase 4)Study completedNCT04705883
What this trial is testing

Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors

Who this might be right for
Vulvar AtrophyBreast CancerGenitourinary Syndrome of Menopause
Hospital Clinic of Barcelona 10
Not applicableStudy completedNCT00997373
What this trial is testing

Letrozole as a Treatment of Endometrial Cancer

Who this might be right for
Endometrial Carcinoma
University of California, Davis 43
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Next Page